Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Pelthos Therapeutics (NYSE American:PTHS) announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference in New York.

Rhea-AI Summary

Pelthos Therapeutics (NYSE American:PTHS) announced that CEO Scott Plesha will present at the 2026 Jefferies Global Healthcare Conference in New York. The presentation is scheduled for 11:05 a.m. ET on June 4, 2026, followed by one-on-one investor meetings arranged through Jefferies representatives.

Argus May 29 session

+2.60% close to close Open Argus

Details

News Market Reaction – PTHS

In the May 29 session, PTHS gained 2.60%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on Pelthos’s participation in the 2026 Jefferies Global Healthcare Confere...

Analysis

This announcement centers on Pelthos’s participation in the 2026 Jefferies Global Healthcare Conference, with the CEO presenting at 11:05 a.m. ET on June 4, 2026. It follows recent earnings highlighting ZELSUVMI growth and a new clinical trial start for CT2000. With an effective $200,000,000 shelf registration in place, investors may watch for updated commercial metrics, clinical timelines, and any indications of future financing strategy discussed around the conference.

Key Figures

Conference date: June 4, 2026 Presentation time: 11:05 a.m. ET Conference year: 2026

Conference date

June 4, 2026

Jefferies Global Healthcare Conference presentation in New York

Presentation time

11:05 a.m. ET

Scheduled CEO presentation slot at Jefferies conference

Conference year

2026

Jefferies Global Healthcare Conference 2026 participation

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Q1 2026 earnings

   24h Move

   +6.5%

   Reported growing ZELSUVMI revenue and narrowed net loss versus prior quarter.

2. May 01

   Earnings date notice

   24h Move

   +0.0%

   Announced timing and access details for upcoming Q1 2026 results call.

3. Apr 14

   Conference participation

   24h Move

   +0.0%

   CEO scheduled for one-on-one investor meetings at Piper Sandler symposium.

4. Apr 10

   CFO transition

   24h Move

   +1.9%

   Appointed new CFO with extensive public company finance experience.

5. Mar 31

   Clinical trial start

   24h Move

   +0.1%

   First patient dosed in Phase 1b/2a trial of CT2000 for eye pain.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, (“Pelthos”), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative.

About Pelthos Therapeutics

Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com 

Media: 
KWM Communications
Kellie Walsh 
pelthos@kwmcommunications.com 
(914) 315-6072

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Pelthos Therapeutics (PTHS) present at the 2026 Jefferies Global Healthcare Conference?

Pelthos Therapeutics will present at 11:05 a.m. ET on June 4, 2026. According to the company, CEO Scott Plesha will speak at the New York conference and meet with investors.

Who is presenting for Pelthos Therapeutics (PTHS) at the 2026 Jefferies Global Healthcare Conference?

CEO Scott Plesha will present for Pelthos Therapeutics at the conference. According to the company, he will give the formal presentation and participate in one-on-one investor meetings.

Where is the 2026 Jefferies Global Healthcare Conference with Pelthos Therapeutics (PTHS) being held?

The 2026 Jefferies Global Healthcare Conference featuring Pelthos Therapeutics will take place in New York. According to the company, the event includes a presentation and investor meetings on June 4, 2026.

How can investors arrange one-on-one meetings with Pelthos Therapeutics (PTHS) at the Jefferies conference?

Investors can arrange one-on-one meetings with Pelthos Therapeutics by contacting their Jefferies representative. According to the company, these meetings will occur around the June 4, 2026 conference presentation.

What is Pelthos Therapeutics' focus as a biopharmaceutical company (PTHS)?

Pelthos Therapeutics focuses on commercializing innovative therapeutic products for unmet patient needs. According to the company, its mission centers on bringing new treatment options to patients through its biopharmaceutical efforts.

What is the ticker symbol for Pelthos Therapeutics participating in the 2026 Jefferies conference?

Pelthos Therapeutics trades on the NYSE American under the ticker symbol PTHS. According to the company, this symbol identifies its shares for investors following the Jefferies Global Healthcare Conference appearance.